Industry & Policy News

[Albatroz Therapeutics (JoplingGlobe)] Albatroz Therapeutics announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis.

[Nature News] Models show that death rates must decline faster to meet Cancer Moonshot goals to cut deaths in half in 25 years.

[Bridge Bio] Biotherapeutics has obtained approval for its investigational new drug (IND) plan to conduct the phase 1.2 clinical trial of the fourth-generation EGFR-mutant non-small cell lung cancer targeted agent, BBT-207, from the U.S. Food and Drug Administration.

[Damon Runyon Cancer Research Foundation] Damon Runyon has announced its 2023 Quantitative Biology Fellows, three exceptional early-career scientists who are applying the tools of computational science to generate and interpret cancer research data at extraordinary scale and resolution.

[IN8bio, Inc.] IN8bio, Inc. announced FDA orphan drug designation for INB-400 and INB-410, covering a broad range of malignant glioma treatments, including newly diagnosedglioblastoma multiforme, marking the first-ever orphan drug designation for genetically modified gamma-delta T cell therapies.

[KFF Health News] The federal government’s public health emergency that’s been in effect since January 2020 is set to expire May 11. Public health legal scholars, data experts, former and current federal officials, and patients at high risk of severe covid outcomes worry the scaling back of data access could make it harder to control covid.